查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511872

美國放射性皮膚炎市場規模、佔有率、趨勢分析報告：按產品類型、分銷管道、設施類型、細分市場預測，2024-2030 年

U.S. Radiodermatitis Market Size, Share & Trends Analysis Report By Product (Topical, Dressings), By Distribution Channel, By Facility Type (Hospital-based Radiotherapy Centers, Independent Radiotherapy Centers), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10個工作天內

價格

美國放射性皮膚炎市場成長與趨勢：

Grand View Research最新報告顯示，到2030年，美國放射性皮膚炎市場規模預計將達到4.8107億美元，2024年至2030年複合年成長率為5.5%。

有幾個重要因素促成了這種成長，包括癌症盛行率的增加、放射治療技術的重大發展以及放射性皮膚炎新治療方案的開發。癌症負擔的增加是推動市場成長的關鍵因素。由於癌症是全世界死亡的主要原因之一，因此對有效放射線治療和放射性皮膚炎的後續治療的需求不斷成長。經常需要放射線治療的癌症類型（例如乳癌和攝護腺癌）的高發生率也有望支持市場擴張。此外，越來越多的老年人更容易罹患癌症等慢性疾病，這也推動了對放射性皮膚炎治療的需求。

放射性皮膚炎新治療方案的開拓，例如局部乳膏、敷料和口服藥物，也有助於市場擴張。這些創新為患者提供了症狀管理的選擇，可能會提高生活品質並降低與嚴重放射性皮膚炎病例相關的醫療費用，但傳統的放射性皮膚炎管理解決方案也可能減少需求。例如，2024年4月，Molnlycke宣布同意收購知名傷口清洗製造商PGF Industry Solutions GmbH。此次收購預計將鞏固該公司作為創傷護理全球領導者的地位。

此外，醫療保健專業人員和患者對管理放射性皮膚炎重要性的認知和教育的提高也影響了成長。這種認知導致人們重視預防措施和早期療育，這對於最大限度地減少放射性皮膚炎的嚴重程度和改善患者的治療效果至關重要。醫療保健提供者、研發和製藥公司之間的合作開發和推廣有效的放射性皮膚炎治療方法正在進一步推動市場擴張。因此，癌症盛行率的增加、放射治療和治療選擇的進步以及對放射性皮膚炎管理的認知和教育的提高的綜合影響預計將有助於該行業的成長。

美國放射性皮膚炎市場報告亮點

  • 2023年，外用製劑銷售額佔75.68%。這一比例是由於廣泛使用外用產品來控制放射性皮膚炎症狀所致。
  • 局部治療，包括乳霜和軟膏，可以直接塗布受影響的區域，立即緩解症狀並降低全身副作用的風險。
  • 2023年，零售藥局領域佔最大的銷售佔有率。這種成長歸因於可及性和便利性。零售藥局是許多尋求非處方治療放射性皮膚炎等疾病的患者的主要接觸點。
  • 2023年，獨立放射治療中心部門佔收益佔有率最大。這是由於我們專注於先進放射治療、減少輻射暴露和提高腫瘤靶向準確性。此外，這些中心通常採取更個人化的方法，這可以提高患者滿意度和重複就診率。
  • 市場參與者正在採取各種策略舉措來擴大其產品在不同地區的覆蓋範圍和可用性。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章美國放射性皮膚炎市場變數、趨勢、範圍

  • 市場體系展望
    • 相關/附隨市場展望
  • 美國各種癌症的發生率
  • 2024年美國各種癌症發生率和死亡率
  • 2024 年美國癌症發生率預測（按州）
  • 2024年美國選擇放射線治療並患有放射性皮膚炎的患者人數
  • 放射性皮膚炎的程度取決於癌症類型
  • 使用臨床參數表徵癌症誘發的放射性皮膚炎
  • 放射治療設施的類型（美國的各種癌症）
  • 放射性皮膚炎治療的平均產品成本
  • 產品市場機會
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 美國放射性皮膚炎市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國放射性皮膚炎市場：產品估算及趨勢分析

  • 美國放射性皮膚炎市場：產品儀表板
  • 美國放射性皮膚炎市場：產品變化分析
  • 2018-2030年美國放射性皮膚炎市場規模、預測與趨勢分析（按產品）
  • 外用
  • 覆蓋材料

第5章美國放射性皮膚炎市場：通路估計與趨勢分析

  • 美國放射性皮膚炎市場：分銷通路儀表板
  • 美國放射性皮膚炎市場：分銷管道波動分析
  • 2018-2030年美國放射性皮膚炎市場規模、預測與趨勢分析（依通路）
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第6章美國放射性皮膚炎市場：設施類型的估計和趨勢分析

  • 美國放射性皮膚炎市場：設施類型儀表板
  • 美國放射性皮膚炎市場：設施類型變化分析
  • 2018-2030 年美國放射性皮膚炎市場規模、預測與趨勢分析（按設施類型）
  • 醫院附設放射治療中心
  • 獨立放射治療中心

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • Stratpharma AG
    • Smith &Nephew plc
    • Molnlycke Health Care AB
    • Derma Sciences Inc
    • Convatec Inc
    • 3M Company
    • Alliqua BioMedical
    • BMG Pharma spA
Product Code: GVR-4-68040-307-1

U.S. Radiodermatitis Market Growth & Trends:

The U.S. radiodermatitis market size is expected to reach USD 481.07 million by 2030, growing at a CAGR of 5.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. Several key factors, including the increasing prevalence of cancer, advancements in radiation therapy techniques, and the development of new treatment options for radiodermatitis are contributing to this growth. The growing burden of cancer is a significant factor driving market growth. With cancer being one of the leading causes of death worldwide, the demand for effective radiation therapy and subsequent management of radiodermatitis is growing. The high incidence of cancer types, such as breast and prostate cancers, which often require radiation therapy, is expected to boost market expansion. Moreover, the growing geriatric population, which is more susceptible to chronic diseases such as cancer, is boosting the demand for radiodermatitis treatment.

The market growth is also affected by the development of new treatment options for radiodermatitis, such as topical creams, dressings, and oral medications, which has expanded the market scope. Although these innovations offer patients more choices in managing their symptoms and potentially lead to improved quality of life & reduced healthcare costs associated with severe cases of radiodermatitis, they may also reduce the demand for traditional radiodermatitis management solutions. For instance, in April 2024, Molnlycke announced an agreement to acquire P.G.F. Industry Solutions GmbH, a prominent wound cleansing manufacturer. This acquisition is expected to help the company strengthen its position as a global leader in wound care.

Moreover, growth is also influenced by the increasing awareness and education among healthcare professionals & patients regarding the importance of managing radiodermatitis. This awareness has led to a greater emphasis on preventive measures and early intervention, which are crucial in minimizing the severity of radiodermatitis & improving patient outcomes. Collaborations between healthcare providers, researchers, and pharmaceutical companies to develop & promote effective radiodermatitis treatments further drive market expansion. Thus, the combined impact of the increasing prevalence of cancer, advancements in radiation therapy & treatment options, and the growing awareness & education about radiodermatitis management is expected to contribute to industry growth.

U.S. Radiodermatitis Market Report Highlights:

  • The topical product segment accounted for a revenue share of 75.68% in 2023. This share can be attributed to the widespread use of topical products in managing the symptoms of radiodermatitis.
  • Topical treatments, including creams & ointments, can be directly applied to the affected area, providing immediate relief and reducing the risk of systemic adverse effects.
  • The retail pharmacies segment held the largest revenue share in 2023. This growth can be attributed to their accessibility and convenience. Retail pharmacies serve as a primary point of contact for many patients seeking over-the-counter treatments for conditions such as radiodermatitis.
  • The independent radiotherapy centers segment held the largest revenue share in 2023. This is due to their focus on advanced radiotherapy treatments, reduced radiation exposure, and increased precision in tumor targeting. Moreover, these centers often have a more personalized approach, which can lead to higher patient satisfaction and repeat business.
  • Market players are undertaking various strategic initiatives to enhance product reach and availability across different geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Distribution channel
    • 1.2.3. Facility type
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. Epidemiology-based Market Analysis
    • 1.8.1. Research Scope and Assumptions
    • 1.8.2. Research Methodology and Assumptions
  • 1.9. List of Secondary Sources
  • 1.10. List of Primary Sources
  • 1.11. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product
    • 2.2.2. Distribution channel
    • 2.2.3. Facility type
  • 2.3. Competitive Insights

Chapter 3. U.S. Radiodermatitis Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Related/ancillary market outlook
  • 3.2. Prevalence of Different Cancer Types in the U.S.
  • 3.3. Incidence and Mortality Rates of Different Cancer Types in the U.S. in 2024
  • 3.4. Expected Cancer Incidence in the U.S. for 2024 (by States)
  • 3.5. Number of Patients Opting for Radiation Therapy and Suffering From Radiodermatitis in the U.S. in 2024
  • 3.6. Grades of Radiodermatitis for Different Cancer Types
  • 3.7. Characterization of Radiodermatitis for Cancer Using Clinical Parameters
  • 3.8. Facility Types for Radiation Therapy (for Different Types of Cancer in the U.S.)
  • 3.9. Average Product Cost for Radiodermatitis Treatment
  • 3.10. Product Market Opportunities
  • 3.11. Market Dynamics
    • 3.11.1. Market driver Analysis
      • 3.11.1.1. Increasing cancer incidence
      • 3.11.1.2. Advancements in radiation therapy
    • 3.11.2. Market restraint analysis
      • 3.11.2.1. High cost of treatment
  • 3.12. U.S. Radiodermatitis Market Analysis Tools
    • 3.12.1. Industry Analysis - Porter's
      • 3.12.1.1. Supplier power
      • 3.12.1.2. Buyer power
      • 3.12.1.3. Substitution threat
      • 3.12.1.4. Threat of new entrant
      • 3.12.1.5. Competitive rivalry
    • 3.12.2. PESTEL Analysis
      • 3.12.2.1. Political landscape
      • 3.12.2.2. Technological landscape
      • 3.12.2.3. Economic landscape

Chapter 4. U.S. Radiodermatitis Market: Product Estimates & Trend Analysis

  • 4.1. U.S. Radiodermatitis Market: Product Dashboard
  • 4.2. U.S. Radiodermatitis Market: Product Movement Analysis
  • 4.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Topical
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1. Corticosteroids
      • 4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Hydrophilic Creams
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Antibiotics
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Others
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Dressings
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.1.1. Hydrogel and Hydrocolloid Dressings
      • 4.5.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.1.2. No Sting Barrier Films
      • 4.5.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.1.3. Honey-Impregnated Gauze
      • 4.5.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.1.4. Silicone-Coated Dressings
      • 4.5.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.5.1.5. Others
      • 4.5.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Radiodermatitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. U.S. Radiodermatitis Market: Distribution Channel Dashboard
  • 5.2. U.S. Radiodermatitis Market: Distribution Channel Movement Analysis
  • 5.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Radiodermatitis Market: Facility Type Estimates & Trend Analysis

  • 6.1. U.S. Radiodermatitis Market: Facility Type Dashboard
  • 6.2. U.S. Radiodermatitis Market: Facility Type Movement Analysis
  • 6.3. U.S. Radiodermatitis Market Size & Forecasts and Trend Analysis, by Facility Type, 2018 to 2030 (USD Million)
  • 6.4. Hospital-based Radiotherapy Centers
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Independent Radiotherapy Centers
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Stratpharma AG
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Type benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. Smith & Nephew plc
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Type benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. Molnlycke Health Care AB
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Type benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Derma Sciences Inc
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Type benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Convatec Inc
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Type benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. 3M Company
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Type benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Alliqua BioMedical
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Type benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. BMG Pharma spA
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Type benchmarking
      • 7.3.9.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 5-year prevalence of different cancer types in the U.S.
  • Table 3 Incidence and mortality rates of different cancer types in the U.S. in 2024
  • Table 4 Average product cost for radiodermatitis treatment in the U.S.
  • Table 5 U.S. radiodermatitis market revenue estimates and forecast, by product, 2018 - 2030 (USD Million)
  • Table 6 U.S. radiodermatitis market revenue estimates and forecast, by facility type, 2018 - 2030 (USD Million)
  • Table 7 U.S. radiodermatitis market analysis revenue estimates and forecast, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8 Key companies undergoing product launches.
  • Table 9 Key companies undergoing partnerships & collaborations
  • Table 10 Key companies undergoing initiating mergers/acquisitions.
  • Table 11 Key companies undergoing other strategies.

List of Figures

  • Fig. 1 U.S. radiodermatitis market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market formulation & validation
  • Fig. 7 Epidemiology-based market analysis
  • Fig. 8 QFD modelling for market share assessment
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot (Product and distribution channel)
  • Fig. 11 Segment snapshot (Facility type)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 5-year prevalence of cancer in the U.S.
  • Fig. 14 Leading cancer types (incidence and mortality)
  • Fig. 15 Top 10 U.S. states contributing to highest cancer cases in 2024
  • Fig. 16 Top 10 U.S. states contributing to breast, colon, rectum, lung and bronchus, and prostate cancer cases in 2024
  • Fig. 17 Estimated patients undergoing radiation therapy and suffering from radiodermatitis in the U.S. for selected cancer types in 2024
  • Fig. 18 Stage wise distribution of cancer patients receiving radiation therapies-I
  • Fig. 19 Stage wise distribution of cancer patients receiving radiation therapies-II
  • Fig. 20 Grade of radiodermatitis for different cancer types
  • Fig. 21 Characterization of radiodermatitis for cancer using clinical parameters
  • Fig. 22 Facility types for radiation therapy in the U.S.
  • Fig. 23 Market opportunity in the U.S.
  • Fig. 24 Market potential for topical and dressing products for radiodermatitis treatment in the U.S.
  • Fig. 26 U.S. Radiodermatitis Market: Product dashboard
  • Fig. 27 U.S. radiodermatitis market: Product movement analysis
  • Fig. 28 U.S. Radiodermatitis facility type dashboard
  • Fig. 29 U.S. radiodermatitis market: Facility type movement analysis
  • Fig. 30 U.S. Radiodermatitis distribution channel dashboard
  • Fig. 31 U.S. radiodermatitis market: Distribution channel movement analysis
  • Fig. 32 Key company categorization
  • Fig. 33 Company market position analysis
  • Fig. 34 Strategic framework